Northland initiates ARS Pharmaceuticals stock with outperform rating By Investing.com

Northland initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform and $25 price target (~205% upside vs $8.19), projecting neffy U.S. peak sales >$1B; Leerink raised its target to $26 and William Blair reiterated Outperform. ARS reported Q4 2025 EPS of -$0.41 vs -$0.4246 consensus (beat by $0.0146) and revenue $28.1M vs $26.9M expected (beat by $1.2M, ~4.5%); FY2025 revenue was $72.2M, roughly in line with the $73M consensus. The FDA removed an age restriction for neffy in the 33–66 lb weight range, improving market access and supporting the bullish analyst thesis.

Analysis

A novel administration format for a staple acute-use drug creates two overlapping adoption bridges: payer coverage/incentive changes and point-of-care substitution in schools/EMS. Expect formulary decisions and PBM contracting to drive discrete step-functions in uptake — a commercial formulary win can move market share within 6–12 months, whereas institutional adoption (school districts, first responders) will ratchet adoption more slowly over 12–36 months due to procurement cycles and training budgets.

Second-order supply effects matter: device assembly and combination-product manufacturing capacity, not active pharmaceutical ingredient supply, will be the first bottleneck. That creates an edge for contract manufacturers with scalable device integration lines and gives incumbents a non-price defensive lever (accelerate manufacturing or strike exclusives with large distributors), potentially compressing new entrant margin even if clinical differentiation is clear.

Key reversal drivers are non-clinical: an adverse PBM rebate outcome, an unexpected safety/regulatory hold, or a rapid emergence of a lower-cost generic device pathway could each truncate the adoption curve. Conversely, early inclusion on major formularies or state Medicaid programs would de-risk revenue visibility materially and de-couple the stock from binary clinical-news volatility over the next 12–18 months.

Key Decisions for Investors

• Long SPRY via a 9–15 month call spread (buy 1x near-term LEAP or 12m ATM call, sell a higher strike) sized 1–2% notional: asymmetric upside (target +80–150% if major PBM/formulary wins within 12 months) versus defined downside limited to premium paid; reduce position by 30% on failure to land a top-3 PBM formulary listing within 6 months.
• Pair trade: long SPRY (smaller size) / short legacy autoinjector incumbent (e.g., VTRS) sized 0.7:1 to reflect volatility — gamma event if conversion accelerates; horizon 12–24 months. Rationale: displacement risk to autoinjectors flows to the incumbent’s multiples; haircut and stop-loss if incumbent announces supply-side countermeasures or large rebate deal.
• Event-driven options hedge: sell 30–60 day covered calls against the long equity exposure once a major PBM inclusion or Medicaid code is confirmed to monetize implied vol compression; target capture of 25–40% of option premium as downside buffer.
• Monitor manufacturability signals and contract manufacturing M&A: set an alert for partner capacity announcements (tooling orders, CMOs taking exclusives) — positive read-through should be traded as a secondary catalyst to add exposure, negative read-through (supply delays) should prompt trimming to protect capital.